Rallybio’s (RLYB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Rallybio (NASDAQ:RLYB) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock. HC Wainwright also issued estimates for Rallybio’s FY2025 earnings at ($1.20) EPS.

Rallybio Stock Down 0.7 %

Shares of Rallybio stock opened at $0.73 on Monday. Rallybio has a twelve month low of $0.62 and a twelve month high of $3.46. The company has a 50-day simple moving average of $0.79 and a two-hundred day simple moving average of $0.97. The stock has a market capitalization of $30.24 million, a price-to-earnings ratio of -0.46 and a beta of -1.45.

Rallybio (NASDAQ:RLYB) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.15 million. On average, sell-side analysts anticipate that Rallybio will post -1.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rallybio

Several hedge funds have recently bought and sold shares of RLYB. Northeast Financial Consultants Inc increased its holdings in Rallybio by 336.5% in the 4th quarter. Northeast Financial Consultants Inc now owns 96,422 shares of the company’s stock valued at $93,000 after buying an additional 74,334 shares during the period. Geode Capital Management LLC grew its holdings in shares of Rallybio by 11.4% during the 3rd quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock valued at $287,000 after purchasing an additional 24,980 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Rallybio by 9.3% during the 4th quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock valued at $424,000 after purchasing an additional 37,618 shares during the last quarter. Allostery Investments LP bought a new stake in shares of Rallybio during the 4th quarter valued at approximately $771,000. Finally, Almitas Capital LLC grew its holdings in shares of Rallybio by 48.3% during the 4th quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock valued at $1,246,000 after purchasing an additional 422,685 shares during the last quarter. 90.34% of the stock is owned by institutional investors.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.